NCT06904807 A Phase I Study to Evaluate LIFE-001
| NCT ID | NCT06904807 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | LifeMine Therapeutics |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2026-11-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 160 participants in total. It began in 2025-04-07 with a primary completion date of 2026-11-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if LIFE-001 is safe and tolerable for healthy adult volunteers.
Eligibility Criteria
Inclusion Criteria: * Female or male between the ages of 18 and 65 years, inclusive * Medically healthy (without significant medical issues, e.g. high blood pressure) * Must provide written informed consent Exclusion Criteria: * Ongoing or history of any psychiatric, medical or surgical condition that might jeopardize the participant's safety or interfere with the absorption, distribution or excretion of the study drug * Any abnormal ECG findings, laboratory value or physical examination findings * Positive ethanol, drug screen or cotinine test * Use of systemic prescription medications or over-the-counter (OTC) medication, including multivitamins, and dietary and herbal supplement within 7 days * Use of any experimental or investigational device within 30 days * Donation or loss of 500 mL or more of blood within 30 weeks and/or donation of plasma within 30 days
Contact & Investigator
Ben Snyder
PRINCIPAL INVESTIGATOR
Veritus Research
Frequently Asked Questions
Who can join the NCT06904807 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06904807 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06904807 currently recruiting?
Yes, NCT06904807 is actively recruiting participants. Contact the research team at clinicaltrials@lifeminetx.com for enrollment information.
Where is the NCT06904807 trial being conducted?
This trial is being conducted at Bayswater, Australia.
Who is sponsoring the NCT06904807 clinical trial?
NCT06904807 is sponsored by LifeMine Therapeutics. The principal investigator is Ben Snyder at Veritus Research. The trial plans to enroll 160 participants.